Related Experiment Videos
[Major depressive disorders and BDNF (brain-derived neurotrophic factor)]
Eiji Shimizu1, Kenji Hashimoto, Masaomi Iyo
1Department of Psychiatry (K2), Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670 Japan.
Nihon Shinkei Seishin Yakurigaku Zasshi = Japanese Journal of Psychopharmacology
|August 5, 2004
Summary
Low levels of brain-derived neurotrophic factor (BDNF) are linked to major depressive disorders. Reduced BDNF may be a key factor in depression, but further research is needed to understand its exact role.
Area of Science:
- Neuroscience
- Psychiatry
- Molecular Biology
Context:
- Major depressive disorders (MDDs) are complex conditions with unclear etiological mechanisms.
- Brain-derived neurotrophic factor (BDNF) is implicated in neuronal survival, growth, and plasticity.
- Previous research suggests a link between BDNF and depression, but the precise role remains debated.
Purpose:
- To review pre-clinical and clinical evidence on BDNF's role in the pathophysiology of major depressive disorders.
- To investigate the relationship between serum BDNF levels and depression in drug-naive patients.
- To explore potential mechanisms, including genetic and environmental factors, contributing to reduced BDNF in depression.
Summary:
- Pre-clinical studies indicate BDNF has antidepressant activity and neuroprotective effects, with expression induced by antidepressants.
- Clinical findings reveal significantly decreased serum BDNF levels in drug-naive patients with depression compared to controls.
- Low BDNF levels may be pivotal in depression pathophysiology, potentially reflecting genetic vulnerability or stress-induced neuronal damage.
Impact:
- Highlights the potential role of BDNF as a biomarker for major depressive disorders.
- Suggests BDNF modulation as a therapeutic target for depression.
- Underscores the need for further research to elucidate the precise mechanisms linking BDNF to depression etiology.